Preventing Tolerance to Oxymetazoline in Allergic Rhinitis

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators wish to evaluate the effects of decongestants like oxymetazoline and the lessening of this effect with time called 'tolerance'. The investigators will demonstrate a reversal of this tolerance with nasal steroids i.e. the investigators will show that nasal steroids protect against tolerance. This will tell us more on how the investigators can make this treatment effective and safe for patients suffering with allergic rhinitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brian J Lipworth
• Treatments: Fluticasone; Oxymetazoline; Phenylephrine; Xhance

Criteria

Inclusion Criteria:

• Male of Female aged 18-65 years.

• Persistent allergic rhinitis with or without asthma.

• Atopy to atleast one allergen on SPT.

• PNIF < 120 L/min (best of 3) and reversibility with OXY >20L/min.

• Ability to give a written informed consent.

• Ability and willingness to comply with the requirements of the protocol.

Exclusion Criteria:

• Recent respiratory tract/sinus infection within the last 2 months. .

• Pregnancy, planned pregnancy or lactation.

• Known or suspected hypersensitivity to any of the IMP's.

• Concomitant use of medicines (prescribed, OTC or herbal) like alpha blockers that may interfere with the trial.

• Nasal Polyposis grade 2+, Deviated nasal septum ≥ 50%

• The use of oral corticosteroids within the last 3 months.